Non-small cell lung cancer stage III
RecruitingPumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
- Disease:Non-small cell lung cancer stage III
- Substances:Durvalumab
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Durvalumab
- Sponsor:Bristol-Myers Squibb Services Unlimited Company















